- Home
- IMNN vs SNSE Comparison
IMNN vs SNSE Comparison
Compare IMNN & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- SNSE
- Stock Information
- Founded
- IMNN 1982
- SNSE 2005
- Country
- IMNN United States
- SNSE United States
- Employees
- IMNN N/A
- SNSE N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- SNSE Health Care
- Exchange
- IMNN Nasdaq
- SNSE Nasdaq
- Market Cap
- IMNN 12.9M
- SNSE 11.2M
- IPO Year
- IMNN 1985
- SNSE 2021
- Fundamental
- Price
- IMNN $5.33
- SNSE N/A
- Analyst Decision
- IMNN Buy
- SNSE Strong Buy
- Analyst Count
- IMNN 2
- SNSE 4
- Target Price
- IMNN $182.61
- SNSE $72.50
- AVG Volume (30 Days)
- IMNN 153.1K
- SNSE 7.3K
- Earning Date
- IMNN 11-06-2025
- SNSE 11-13-2025
- Dividend Yield
- IMNN N/A
- SNSE N/A
- EPS Growth
- IMNN N/A
- SNSE N/A
- EPS
- IMNN N/A
- SNSE N/A
- Revenue
- IMNN N/A
- SNSE N/A
- Revenue This Year
- IMNN N/A
- SNSE N/A
- Revenue Next Year
- IMNN N/A
- SNSE N/A
- P/E Ratio
- IMNN N/A
- SNSE N/A
- Revenue Growth
- IMNN N/A
- SNSE N/A
- 52 Week Low
- IMNN $4.70
- SNSE $5.00
- 52 Week High
- IMNN $41.22
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- IMNN 47.96
- SNSE 73.13
- Support Level
- IMNN $5.04
- SNSE $9.35
- Resistance Level
- IMNN $5.55
- SNSE $10.00
- Average True Range (ATR)
- IMNN 0.29
- SNSE 0.48
- MACD
- IMNN 0.04
- SNSE 0.16
- Stochastic Oscillator
- IMNN 70.94
- SNSE 100.00
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).